Nanobiotix SA（NBTX）の株式分析NBTXNanobiotix SA

Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo. It operates in the Healthcare sector.

Currently, Nanobiotix SA (NBTX) is trading at $41.79, which is significantly below the analyst price target of EUR 60 from H.C. Wainwright, indicating potential upside. However, the stock has a high forward P/E ratio of 119.05, suggesting that it may be overvalued based on future earnings expectations. Additionally, insider activity shows a neutral trend, while hedge funds are selling with a 1048.78% increase in selling over the last quarter, indicating potential caution among institutional investors. Given these factors, it may be wise to hold off on buying until further clarity on the company's upcoming Phase 3 trial results and market sentiment improves.